FindTrial
Sign In

Application and effect of omega-3 fatty acid component formula food in patients with pulmonary infection

Application and effect of omega-3 fatty acid component formula food in patients with pulmonary infection

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043173
Enrollment
Unknown
Registered
2021-02-07
Start date
2021-02-20
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary infection

Interventions

Low dose Experimental group: 2 grams containing omega-3 fatty acid components:Omega-3 fatty acids are added to all-day enteral nutrition
High dose Experimental group: 5 grams containing omega-3 fatty acid components:Omega-3 fatty acids are added to all-day enteral nutrition
Placebo group: No omega-3 fatty acids:All-day enteral nutrition support without omega-3 fatty acids

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) The age ranged from 18 to 90 years old; (2) Patients are diagnosed with pulmonary infection; (3) Indications of enteral nutrition support: difficulty in oral feeding, dyspepsia, nutritional risk or malnutrition with intestinal tolerance; (4) Invasive ventilator-assisted breathing and non-invasive ventilator-assisted breathing were performed; (5) Nasogastric tube, gastrostomy tube, nasointestinal nutrition tube and enterostomy nutrition tube were placed; (6) The informed consent shall be signed by the patient or his/her legal guardian or authorized consignor.

Exclusion criteria

Exclusion criteria: (1) Contraindications of enteral nutrition: severe acute pancreatitis, intestinal obstruction, intractable vomiting, large amount of upper gastrointestinal bleeding, peritonitis, extensive small bowel resection, etc.; (2) Patients are allergic to omega-3 fatty acids; (3) Patients with severe diarrhea before the trial; (4) Pregnant or lactating women; (5) Fecal incontinence; (6) Participating in other clinical trials; (7) The patients who undergo surgery of grade 3 or above in recent three months; (8) Cancer patients; (9) Patients with fungal and viral infection for the first diagnosis; (10) Other researchers think that patients are not suitable for this study.

Design outcomes

Primary

MeasureTime frame
Serum CRP;umor necrosis factor (TNF-a);Interleukin- 6(IL-6);procalcitonin (PCT);Routine blood;—

Secondary

MeasureTime frame
physical examination;Immunoglobulin (IgG, IgA, IgM);T cell subsets (CD3, CD4, CD8);blood gas analysis;Prealbumin (PAB);Serum albumin;—

Countries

China

Contacts

Public ContactZhiyong Rao

West China Hospital of Sichuan University

raoyong100@126.com+86 18980602276

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026